Chronic plasma exchange therapy in SLE nephritis.
Eight patients who met the clinical, immunological and renal morphologic criteria for systemic lupus erythematosus with diffuse proliferative nephritis were plasma exchanged on a monthly basis for a total of 119 months. Renal function, episodes of disease activity, hospitalizations, frequency of immunological abnormalities, and monthly quantity of steroid and azathioprine therapy were compared with their course up to one year prior to the onset of the plasma exchange program. The changes noted in these parameters indicate that chronic plasma exchange therapy is safe, may be beneficial and requires controlled prospective study to determine the role in the treatment of patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis.
D001379:Azathioprine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008297:Male; D009393:Nephritis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D010951:Plasma Exchange; D011241:Prednisone / Q000627:therapeutic use
D001379:Azathioprine; D011241:Prednisone